

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

2. Authorization for this examiner's amendment was given in a telephone interview with Ms. Sunhee Lee on June 16, 2010.

3. The application has been amended as follows:

Claim 40 has been amended to read in favor of:

---40. (Currently amended, rejoined): A method for treating a disease related to EDG-1 and/or EDG-6 in a mammal, which comprises administering to the mammal an effective amount of the compound represented by formula (IA-2-1) according to claim 1, or a salt thereof wherein the disease is rejection in transplantation of kidney, liver, heart, lung, dermal graft, cornea, bone, bone marrow cells, pancreatic islet cells, collagen disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, lupus nephritis, lymphoma, malignant tumor, psoriasis, inflammatory bowel disease, Crohn's disease, autoimmune diabetes, lung fibrosis, atopic dermatitis and/or asthma.--.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

4. Based upon the response filed June 8, 2010, the finality of the Office Action mailed March 8, 201 is withdrawn.

Art Unit: 1625

5. Based upon the response filed June 8, 2010, the rejection under 35 U.S.C. 112, 1st paragraph, 35 U.S.C. 112, 2nd paragraph, and 35 U.S.C. 102(b) based upon Warrener et al. are withdrawn.

6. Non elected claims 40 and 41 are rejoined with the elected invention

7. In order to meet the requirements of 35 U.S.C. 112, 1st paragraph, claim 40 has been amended. At pages 16-17, support for the changes is found.

8. The changes made by Examiner's Amendment are editorial in nature. The changes are not made to avoid any possible rejections based upon prior art.

9. The examiner has provided a signed copy of the references considered on the Information Disclosure Statement filed February 28, 2006.

10. The Information Disclosure Statement filed May 28, 2010 has been considered. The references alone or in combination forms do not teach nor suggest the invention as instantly claimed. There is no motivation to modify the prior art compounds to derive the compounds as claimed. Accordingly, claims 1,5, 16, 19, 20, 22, 25, 27-35, and 37-41 are allowed.

11. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is 571-272-0682.

Art Unit: 1625

13. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Zinna Northington Davis
Zinna Northington Davis
Primary Examiner
Group 1600-AU 1625